Eif4E Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| EIF4E Protein | |
|---|---|
| Protein Name | Eukaryotic Translation Initiation Factor 4E |
| Gene | [EIF4E](/genes/eif4e) |
| UniProt ID | [P06730](https://www.uniprot.org/uniprot/P06730) |
| Aliases | eIF4E, 4E, EIF4EL3 |
| Molecular Weight | 25 kDa |
| Protein Family | eIF4E cap-binding protein family |
| Subcellular Localization | Cytoplasm, P-bodies, Stress granules |
| Expression | Ubiquitous, brain (high) |
EIF4E (Eukaryotic Translation Initiation Factor 4E) is the cap-binding subunit of the eIF4F complex, which is essential for cap-dependent mRNA translation initiation. eIF4E recognizes the 7-methylguanosine cap (m7GpppN) at the 5' end of mRNAs and, together with eIF4G and eIF4A, forms the eIF4F complex that recruits the 40S ribosomal subunit to mRNAs. Beyond its canonical role in translation, eIF4E has diverse functions in mRNA export, stability, and localization. In the nervous system, eIF4E is critical for synaptic plasticity, memory formation, and neuronal responses to activity. Dysregulation of eIF4E activity is implicated in Alzheimer's disease, Parkinson's disease, and autism spectrum disorders, making it an important therapeutic target.
eIF4E is a 217 amino acid protein with a characteristic "cupped hand" structure:
The protein adopts an eight-stranded antiparallel β-sheet that forms a curved structure resembling a cupped hand, with the cap-binding pocket on the convex side.
eIF4E is essential for cap-dependent translation initiation:
Canonical Translation:
mRNA Metabolism:
Neuronal Functions:
eIF4E is significantly implicated in AD:
In PD:
eIF4E dysregulation is linked to:
eIF4E is a promising therapeutic target:
| Drug/Strategy | Mechanism | Status |
|---|---|---|
| 4EGI-1 | eIF4E/eIF4G interaction inhibitor | Research |
| Ribavirin | eIF4E inhibitor (antiviral repurposed) | Research |
| 4E-BP1 Overexpression | Endogenous eIF4E inhibitor | Preclinical |
| mTOR Inhibitors | Indirect eIF4E regulation | Clinical |
| eIF4E siRNA | Gene silencing | Preclinical |
Challenges:
eIF4E activity can be assessed through:
The study of Eif4E Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.